Drug intelligence / Profile preview

CTH-400

Development stage: Preclinical
Lead developer: Cartherics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTH-400 is a preclinical cell therapy drug candidate developed by Cartherics. It is a CAR-NK (chimeric antigen receptor natural killer) cell therapy designed to target tumor-associated glycoprotein 72 (TAG-72), which is commonly expressed on the surface of various cancer cells. The mechanism of action involves inhibition of TAG-72, aiming to direct the immune system's NK cells to recognize and destroy neoplastic (cancerous) cells expressing this antigen. Its primary indication is for neoplasms (cancers), and it has not yet entered clinical trials[1].

Targets

TAG-72

Beyond the preview

Go deeper on CTH-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-400.

Explore the full profile